NUMED HOME HEALTH CARE INC
SC 13D/A, 1997-01-28
HOME HEALTH CARE SERVICES
Previous: SCOTTS COMPANY, 8-K, 1997-01-28
Next: MICROCHIP TECHNOLOGY INC, S-3MEF, 1997-01-28



<PAGE>
<PAGE>   1
                                  UNITED STATES
                        SECURITIES AND EXCHANGE COMMISSION
                              Washington, D.C. 20549

                                   SCHEDULE 13D

                  Under the Securities and Exchange Act of 1934
                               (Amendment No. 1)*

                           NuMED HOME HEALTH CARE, INC.
- -------------------------------------------------------------------------------
                                 (Name of Issuer)

                                   Common Stock
- -------------------------------------------------------------------------------
                          (Title of Class of Securities)

                                    67052T201
- -------------------------------------------------------------------------------
                                  (CUSIP Number)

                 Marc C. Krantz, Kohrman Jackson & Krantz P.L.L.,
            1375 East 9th Street, Cleveland, Ohio 44114, 216-736-7204
- -------------------------------------------------------------------------------
             (Name, Address and Telephone Number of Person Authorized
                      to Receive Notices and Communications)

                                January 22, 1997
- -------------------------------------------------------------------------------
             (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].

Check the following box if a fee is being paid with the statement [X].  (A fee
is not required only if the reporting person:  (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.) 
(See Rule 13d-7.)

Note:  Six copies of this statement, including all exhibits, should be filed
with the Commission.  See Rule 13d-1(a) for other parties to whom copies are to
be sent.

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE>
<PAGE>   2
<TABLE>
                                   SCHEDULE 13D
CUSIP NO. 67052T201
<S>  <C>
- -------------------------------------------------------------------------------
1    NAME OF REPORTING PERSON
     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
     Turkey Vulture Fund XIII, Ltd.
- -------------------------------------------------------------------------------
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*                 (a) [ ]
                                                                       (b) [ ]
- -------------------------------------------------------------------------------
3    SEC USE ONLY

- -------------------------------------------------------------------------------
4    SOURCE OF FUNDS*
     WC
- -------------------------------------------------------------------------------
5    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
     TO ITEMS 2(d) or 2(e)                                                 [ ]
- -------------------------------------------------------------------------------
6    CITIZENSHIP OR PLACE OF ORGANIZATION
     Ohio
- -------------------------------------------------------------------------------
       NUMBER OF         7    SOLE VOTING POWER

        SHARES                390,000
                         ------------------------------------------------------
     BENEFICIALLY        8    SHARED VOTING POWER

       OWNED BY
                         ------------------------------------------------------
         EACH            9    SOLE DISPOSITIVE POWER

      REPORTING               390,000
                         ------------------------------------------------------
        PERSON           10   SHARED DISPOSITIVE POWER

         WITH
- -------------------------------------------------------------------------------
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     390,000
- -------------------------------------------------------------------------------
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*[ ]
- -------------------------------------------------------------------------------
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     8.0%
- -------------------------------------------------------------------------------
14   TYPE OF REPORTING PERSON*
     OO
- -------------------------------------------------------------------------------
</TABLE>

<PAGE>
<PAGE>   3
CUSIP No. 67052T201

     This Amendment No. 1 to Schedule 13D Statement is filed on behalf of
Turkey Vulture Fund XIII, Ltd., an Ohio limited liability company (the "Fund"),
for the purpose of reporting an acquisition by the Fund of shares of common
stock, par value $0.001 per share (the "Shares"), of NuMed Home Health Care,
Inc., a Nevada corporation ("NuMed").


Item 3.   Source and Amount of Funds or Other Consideration.

     Item 3 is amended and supplemented as follows:

     The Shares reported herein as having been acquired by the Fund were
acquired for the aggregate purchase price of approximately $88,000.  The Fund
purchased such Shares with its working capital.

Item 4.   Purpose of Transaction.

     Item 4 is amended and supplemented as follows:

     Mr. Osborne has met, and expects to continue to meet, with the management
of NuMed to discuss its business strategies. Mr. Osborne may, upon review of
relevant information about the business and operations of NuMed, propose
changes in the business strategies of NuMed.

Item 5.   Interest in Securities of the Issuer.

     Item 5 is amended and supplemented as follows:

     (a)  According to the most recently available filing with the Securities
and Exchange Commission by NuMed, there are 4,903,916 Shares outstanding.

     The Fund beneficially owns 390,000 Shares, or approximately 8.0% of the
outstanding Shares.  Because Mr. Osborne is sole manager of the Fund, Mr.
Osborne may be deemed to beneficially own such Shares.

     (b)  Mr. Osborne, as sole manager of the Fund, has sole power to vote, or
to direct the voting of, and the sole power to dispose or to direct the
disposition of, the 390,000 Shares owned by the Fund.

     (c)  During the past 60 days, the Fund purchased 50,000 Shares in one open
market transaction on January 22, 1997 for $1.75 per Share, excluding
commissions.
 
     (d)  Not Applicable.

     (e)  Not Applicable.
<PAGE>
<PAGE>   4
CUSIP No. 67052T201

     After reasonable inquiry and to the best of my knowledge and belief, I

certify that the information set forth in this statement is true, complete and

correct.


Dated: January 28, 1997                 TURKEY VULTURE FUND XIII, LTD.


                                        By: /s/ Richard M. Osborne
                                           ---------------------------
                                           Richard M. Osborne, Manager





© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission